ESMO 2020 Expert Video Report on studying further advanced ovarian cancer

Reporting from the ESMO Virtual Congress 2020, Sandro Pignata features results from the ovarian cancer studies performed in the advanced setting, IMagyn050/GOG 3015/ENGOT-OV39 which explored a combination of bevacizumab with immune checkpoint inhibitor atezolizumab, and PAOLA-1 about maintenance treatment with a combination of olaparib and bevacizumab that confirmed the important role of PARP inhibitors in the management of ovarian cancer. He also discusses the results from the INOVATYON trial looking at t